Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 36Genitourinary 9Gynecologic 7Gastrointestinal 6Endocrine 6Head & Neck 5Other solid neoplasm 4Sarcoma 3NET 3Breast 3Lymphoid 2Dermatologic 2CNS 2

Conditions

Neuroendocrine Tumors 394Carcinoid Tumor 49Gastro-enteropancreatic neuroendocrine tumor 42Neoplasms 36Carcinoma, Neuroendocrine 36Adenoma, Islet Cell 27Neoplasm Metastasis 23Pancreatic Neoplasms 22Colorectal Neoplasms 21Pheochromocytoma 20Paraganglioma 19Sarcoma 15Gastrointestinal Neoplasms 15Carcinoma 14Breast Neoplasms 14Stomach Neoplasms 13Prostatic Neoplasms 13Neuroblastoma 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Thyroid Neoplasms 12Small Cell Lung Carcinoma 12Carcinoma, Renal Cell 11Cholangiocarcinoma 10Neuroectodermal Tumors, Primitive 9Carcinoma, Non-Small-Cell Lung 9Somatostatinoma 8Serotonin Syndrome 8Digestive System Neoplasms 8Brain Neoplasms 8

Interventions

taxane 1pembrolizumab 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Pemetrexed 1Paclitaxel 1PT-100 dipeptide 1Irinotecan 1Gemcitabine 1Etoposide 1Cisplatin 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Small Cell × NET × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT05500391 2026-03-18

SUR-CAN

Centre Oscar Lambret

Phase 2 Recruiting
88 enrolled
CNSEndocrineGastrointestinalNETSarcoma

Carcinosarcoma, Glioma, Seminoma, Adenocarcinoma, Clear Cell, Carcinoma, Small Cell, Sex Cord-Gonadal Stromal Tumors, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡